A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
CRA-026440 is a novel, broad-spectrum, hydroxamic acid -based inhibitor of histone deacetylase (HDAC) that shows antitumor and antiangiogenic activities in vitro and in vivo preclinically. CRA-026440 inhibited pure recombinant isozymes HDAC1, HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range.doi:10.1158/1535-7163.mct-06-0042 pmid:16891455 fatcat:bkqsz5vzp5gdzbgb2e4prdbtue